ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Buy” by Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has received a consensus recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $172.00.

Several analysts recently issued reports on ICUI shares. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 27th. Piper Sandler cut their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th.

ICU Medical Trading Up 0.9%

ICU Medical stock opened at $158.77 on Wednesday. The firm has a market cap of $3.97 billion, a PE ratio of 85.82, a P/E/G ratio of 2.20 and a beta of 0.76. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The stock’s 50 day simple moving average is $142.12 and its two-hundred day simple moving average is $139.41. ICU Medical has a 12 month low of $107.00 and a 12 month high of $162.85.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts anticipate that ICU Medical will post 6.51 earnings per share for the current year.

Insider Activity at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently modified their holdings of ICUI. Hilton Head Capital Partners LLC acquired a new position in ICU Medical in the 4th quarter worth $32,000. Covestor Ltd grew its holdings in shares of ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares during the last quarter. Strs Ohio lifted its position in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. boosted its position in shares of ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new stake in ICU Medical during the 4th quarter valued at $120,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.